Cytokinetics and Astellas Pharma Inc. provided an update for their collaborative skeletal muscle program

including clinical trial updates for reldesemtiv in neuromuscular and non-neuromuscular conditions. In addition to reldesemtiv, the companies are advancing another fast skeletal muscle troponin activator (FSTA) into Investigational New Drug (IND)-enabling studies and continuing their joint research program through 2019. Cytokinetics has been developing reldesemtiv as a potential treatment for… Att fortsätt läsa

Phase II clinical trials with Reldesemtiv (CK-2127107) in Patients with Spinal Muscular Atrophy (SMA II-III)

presented in an oral presentation by John W. Day, MD, Ph.D., Professor of Neurology and Paediatrics (Genetics), Stanford University. This hypothesis-generating study met its primary goal. It fulfills the effect and safety profile. In collaboration with Astellas, Cytokinetics is developing reldesemtiv as a potential treatment for people with SMA and… Att fortsätt läsa

Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy

to be Presented at the 2018 Annual Cure SMA Conference on June 16, 2018 SOUTH SAN FRANCISCO, Calif., June 08, 2018 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented in… Att fortsätt läsa

Cytokinetik presenterar nya resultat från den fas II kliniska studien av Reldesemtiv vid patienter med typ II, II IV , spinal muskelatrofi

Den kliniska studien utformades för att undersöka effekter av reldesemtiv, en snabbverkande skelettmuskel troponinaktivator i nästa generation (FSTA), på flera mått av muskelfunktion vid ambulatoriska och icke-ambulatoriska patienter med SMA. Studien omfattade 70 patienter, 39 i kohort 1 och 31 i kohort 2. Patienter (typ III eller typ IV) och… Att fortsätt läsa